EDITORIAL
Published on 08 Sep 2023
Editorial: Optimizing outcomes and addressing adversities of immunotherapy in lung cancer
doi 10.3389/fonc.2023.1277542
- 894 views
- Frontiers in Oncology
- Thoracic Oncology
- Research Topics
- Optimizing Outcomes and Addressing Adversities of Immunotherapy in Lung Cancer
Optimizing Outcomes and Addressing Adversities of Immunotherapy in Lung Cancer
13k
Total downloads
39k
Total views and downloads
Submit your idea
You will be redirected to our submission process.
Articles
MINI REVIEW
Published on 08 Dec 2022
Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer
doi 10.3389/fonc.2022.962947
- 1,708 views
- 7 citations
MINI REVIEW
Published on 29 Nov 2022
Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?
doi 10.3389/fonc.2022.996554
- 1,754 views
ORIGINAL RESEARCH
Published on 21 Nov 2022
Prognostic and predictive value of YTHDF1 and YTHDF2 and their correlation with tumor-infiltrating immune cells in non-small cell carcinoma
doi 10.3389/fonc.2022.996634
- 1,174 views
- 1 citation
ORIGINAL RESEARCH
Published on 09 Nov 2022
PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study
doi 10.3389/fonc.2022.909721
- 1,885 views
- 4 citations
ORIGINAL RESEARCH
Published on 08 Nov 2022
Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making
doi 10.3389/fonc.2022.972972
- 1,680 views
- 5 citations
ORIGINAL RESEARCH
Published on 14 Oct 2022
Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer
doi 10.3389/fonc.2022.956755
- 1,786 views
- 4 citations
ORIGINAL RESEARCH
Published on 14 Sep 2022
Hospitalized cancer patients with comorbidities and low lymphocyte counts had poor clinical outcomes to immune checkpoint inhibitors
doi 10.3389/fonc.2022.980181
- 1,060 views
BRIEF RESEARCH REPORT
Published on 13 Sep 2022
Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
doi 10.3389/fonc.2022.843116
- 1,169 views
- 1 citation
ORIGINAL RESEARCH
Published on 09 Sep 2022
Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study
doi 10.3389/fonc.2022.904644
- 4,077 views
- 9 citations
BRIEF RESEARCH REPORT
Published on 07 Sep 2022
Impact of the interval between neoadjuvant immunochemotherapy and surgery on surgical–pathological outcomes in non-small cell lung cancer
doi 10.3389/fonc.2022.909726
- 1,508 views
- 5 citations
CASE REPORT
Published on 02 Sep 2022
PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review
doi 10.3389/fonc.2022.961266
- 1,698 views
- 5 citations
Published in
Frontiers in Oncology
- Thoracic Oncology
Impact
- 39kTopic views
- 25kArticle views
- 13kArticle downloads